<SEC-DOCUMENT>0001193125-19-178045.txt : 20190621
<SEC-HEADER>0001193125-19-178045.hdr.sgml : 20190621
<ACCEPTANCE-DATETIME>20190621060556
ACCESSION NUMBER:		0001193125-19-178045
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190621
FILED AS OF DATE:		20190621
DATE AS OF CHANGE:		20190621

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		19909765

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d768092d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated June 21, 2019 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 12, 95 Pitt Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sydney, 2000 New South Wales, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by
furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Immutep Announces Australian Patent Granted for Eftilagimod Alpha in Chemo-Immunotherapy</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: June 21, 2019 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U></U>Title:&nbsp;&nbsp;&nbsp;Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d768092dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g768092g50p65.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP ANNOUNCES AUSTRALIAN PATENT GRANTED FOR EFTILAGIMOD ALPHA </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IN CHEMO-IMMUNOTHERAPY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY,
AUSTRALIA &#150; </B><B>21</B><B></B><B>&nbsp;June 2019 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the Company&#148;), a biotechnology company developing novel immunotherapy treatments for cancer and
autoimmune diseases, is pleased to announce the grant of a new patent (number<B> </B>2014368420) entitled &#147;Combined Preparations for the Treatment of Cancer&#148; by the Australian Patent Office. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Australian patent follows the recent grant of the corresponding European patent (announced 23&nbsp;May 2019) and protects Immutep&#146;s intellectual
property relating to combined therapeutic preparations comprising its lead active immunotherapy candidate eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;) and a chemotherapy agent. The chemotherapy agent is either a platinum-based
anti-neoplastic agent, such as oxaliplatin or carboplatin, or a topoisomerase I inhibitor, such as topotecan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The new patent again highlights the broad
potential of efti as an immunostimulant and provides patent protection in Australia for a range of novel and highly relevant chemo-immunotherapies featuring efti that may be pursued in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent expiry date is 19&nbsp;December 2034. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a globally active biotechnology company that is a leader in the development of immunotherapeutic products for the treatment of
cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep&#146;s current lead product is eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;), a soluble <FONT STYLE="white-space:nowrap">LAG-3Ig</FONT>
fusion protein based on the <FONT STYLE="white-space:nowrap">LAG-3</FONT> immune control mechanism. This mechanism plays a vital role in the regulation of the T cell immune response. Efti is currently in a Phase IIb clinical trial as a
chemoimmunotherapy for metastatic breast cancer termed AIPAC (clinicaltrials.gov identifier NCT02614833); a Phase II clinical trial referred to as <FONT STYLE="white-space:nowrap">TACTI-002</FONT> (Two ACTive Immunotherapies) to evaluate a
combination of efti with KEYTRUDA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pembrolizumab) in several different solid tumours (clinicaltrials.gov identifier NCT03625323); a Phase I clinical trial referred to as <FONT
STYLE="white-space:nowrap">INSIGHT-004</FONT> to evaluate a combination of efti with avelumab (clinical trials.gov identifier NCT03252938); and a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel (clinicaltrials.gov
identifier NCT02676869). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">LAG-3</FONT> products, including antibodies, for immune response modulation in
autoimmunity and cancer are being developed by Immutep&#146;s large pharmaceutical partners. Immutep is also developing an agonist of <FONT STYLE="white-space:nowrap">LAG-3</FONT> (IMP761) for autoimmune disease. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g768092g50p65.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is listed on the Australian Securities
Exchange (IMM), and on the NASDAQ (IMMP) in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information can be found on the Company&#146;s website <U>www.immutep.com</U> or
by contacting: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matthew
Gregorowski, Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 2 8234 0105; <U>mgregorowski@citadelmagnus.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jay Campbell, Chief Business Officer,
Immutep Limited </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (917) <FONT STYLE="white-space:nowrap">860-9404;</FONT> <U>jay.campbell@immutep.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Garth Russell, LifeSci Advisors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (646) <FONT
STYLE="white-space:nowrap">876-3613;</FONT> <U>garth@lifesciadvisors.com</U> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g768092g50p65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g768092g50p65.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1"617AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0=NH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %-H87=N(%!A
M8FQO   !ZAP !P  " P   AH     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MN^\/Z@^IZ':W4N/,=</@8^8'!_E51E=V9I1J\SY9;FG1116ATA1110 4444
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MY/\ 6O5E547"J%'H!3?*C#9")N!Z[10Z=TO(4L/=15_A(M2_Y!5W_P!<'_\
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M7FL+.Z.ZZM8)O>2,-_.@#RZ3XJZK=2110VEO;!I%W,N78C/(&>.?I7<^.O\
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M45P?_"QI?^@:O_?[_P"M1_PL:7_H&K_W^_\ K4>TAW#ZU2[G>45P?_"QI?\
MH&K_ -_O_K4?\+&E_P"@:O\ W^_^M1[2'</K5+N=Y17!_P#"QI?^@:O_ '^_
M^M1_PL:7_H&K_P!_O_K4>TAW#ZU2[G>45P?_  L:7_H&K_W^_P#K4?\ "QI?
M^@:O_?[_ .M1[2'</K5+N=Y17!_\+&E_Z!J_]_O_ *U'_"QI?^@:O_?[_P"M
M1[2'</K5+N=Y17!_\+&E_P"@:O\ W^_^M1_PL:7_ *!J_P#?[_ZU'M(=P^M4
MNYWE%<'_ ,+&E_Z!J_\ ?[_ZU'_"QI?^@:O_ '^_^M1[2'</K5+N=Y17!_\
M"QI?^@:O_?[_ .M1_P +&E_Z!J_]_O\ ZU'M(=P^M4NYWE%<'_PL:7_H&K_W
M^_\ K4?\+&E_Z!J_]_O_ *U'M(=P^M4NYWE%<'_PL:7_ *!J_P#?[_ZU'_"Q
MI?\ H&K_ -_O_K4>TAW#ZU2[G>45P?\ PL:7_H&K_P!_O_K4?\+&E_Z!J_\
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M7_H&K_W^_P#K4>TAW#ZU2[G>45P?_"QI?^@:O_?[_P"M1_PL:7_H&K_W^_\
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HG\Z** #<?4_G1N/J?SHHH -Q]3^=+N/J?SHHH$R%C\Y^M%%%,D__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
